At a glance
- Originator Merck & Co
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 16 Dec 1996 No-Development-Reported for Cerebral ischaemia in USA (Unknown route)